CYBN:NYE-Cybin Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.2102

Change

0.00 (0.00)%

Market Cap

USD 0.16B

Volume

3.76M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-08 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

N/A

USD 585.29B
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD 3.60B
RCUS Arcus Biosciences Inc

N/A

USD 1.64B
NUVB Nuvation Bio Inc

N/A

USD 0.70B
ANRO Alto Neuroscience, Inc.

N/A

USD 0.37B
DNA Ginkgo Bioworks Holdings

N/A

USD 0.35B
ADCT ADC Therapeutics SA

N/A

USD 0.30B
ANVS Annovis Bio Inc

N/A

USD 0.10B
MAIA MAIA Biotechnology Inc.

N/A

USD 0.08B
ARMP Armata Pharmaceuticals Inc

N/A

USD 0.08B

ETFs Containing CYBN

PSIL AdvisorShares Psychedelic.. 8.50 % 0.00 %

N/A

USD 4.62M
PSY 0.00 % 0.76 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -48.73% 38% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.73% 38% F 3% F
Trailing 12 Months  
Capital Gain -36.30% 39% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.30% 39% F 6% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -21.11% 26% F 3% F
Dividend Return -21.11% 26% F 3% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.56% 84% B 32% F
Risk Adjusted Return -66.90% 10% F 4% F
Market Capitalization 0.16B 77% C+ 33% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector